Abstract:Treatment for Alzheimer’s disease (AD) has faced the difficult challenge of effectively targeting and clearing toxic and/or propagative species of protein, which together lead to pathology and neurodegeneration. Current evidence points to a cascade of aberrant proteostasis, generally involving cytotoxic tau pathology that is induced by misfolded Aβ oligomer [1,2,3]. A method for identifying antibodies to Aβ that are conformationally-selective to the toxic oligomer, and which also have relatively low affinity to either Aβ monomer or fibril, is thus a highly desired goal that holds significant promise for AD therapy [4]. We employ computational simulations, using molecular dynamics with standardized force-fields. An experimentally-validated structural model of a protofibrillar aggregate is globally biased away from its “native” conformation to be partially unfolded, using molecular dynamics with collective coordinates to yield a set of regions of contiguous primary sequence that are prone to be disordered upon an external challenge in an anomalous cellular environment. We hypothesize these weakly-stable regions are likely to be exposed in nascent protofibrils or oligomers, and that in this context they are present in an alternate conformation than they are either in the free monomer ensemble or in the context of the fibril. They thus constitute oligomer-specific epitope predictions. Oligomer-specific epitope predictions will be presented for Aβ. Cyclic peptides of these epitope primary sequences are both computationally and experimentally generated, which constitute antigenic targets. Clustering analysis, curvature, exposure to solvent, solubility, dihedral angle distribution, and Ramachandran angle distributions are all used to characterize the conformational properties of predicted epitopes, which quantify the distinction between the antigenic profile when presented in the context of the oligomer from that in either the monomer or fibril. A set of five oligomer-specific epitopes are proposed for Aβ. The computational epitope discovery approach has the potential to produce multiple Aβ oligomer-specific antibodies. Acknowledgements: ProMIS Neurosciences, the Canadian Institutes of Health Research and the Alberta Prion Research Institute. [1] Hadley, KC et al. eLife(2015). [2] Ittner LM, Gotz J, Nat Rev Neurosci (2011). [3] Vasconcelos B et al. Acta Neuropathol (2016). [4] Sevigny J, et al. Alzheimers Dement (2015).

Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM

Development of a Time-Resolved Fluorescence Resonance Energy Transfer ultra-high throughput screening assay for targeting SYK and FCER1G interaction

Development of a time-resolved fluorescence resonance energy transfer ultra-high throughput screening assay targeting SYK and FCER1G interaction

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

TYK2 as a novel therapeutic target in Alzheimer Disease

Discovery of a Novel Chemotype As DYRK1A Inhibitors Against Alzheimer’s Disease: Computational Modeling and Biological Evaluation

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

TYK2 as a novel therapeutic target in Alzheimer's Disease with TDP-43 inclusions

Disruption of DYRK1A-induced hyperphosphorylation of amyloid-beta and tau protein in Alzheimer's disease: An integrative molecular modeling approach

Antagonists Targeting Eef2 Kinase Rescue Multiple Aspects of Pathophysiology in Alzheimer's Disease Model Mice

Syk inhibitors reduce tau protein phosphorylation and oligomerization

Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors

Fyn Kinase in Alzheimer's Disease: Unraveling Molecular Mechanisms and Therapeutic Implications

Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formation

Discovery of a dual-action small molecule that improves neuropathological features of Alzheimer’s disease mice

c-KIT inhibitors reduce pathology and improve behavior in the Tg(SwDI) model of Alzheimer's disease

Optimization of a series of potent, selective and orally bioavailable SYK inhibitors

Development of p-Tau Differentiated Cell Model of Alzheimer's Disease to Screen Novel Acetylcholinesterase Inhibitors

A COMPUTATIONAL METHOD TO PREDICT DISEASE-SPECIFIC EPITOPES IN Aβ, AND ITS APPLICATION TO OLIGOMER-SELECTIVE ANTIBODIES FOR ALZHEIMER’S IMMUNOTHERAPY

ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders

Computational identification of promising therapeutics via BACE1 Targeting: Implications for Alzheimer's disease